The majority of these earlier studies showed that NPM1 mutation without FLT3ITD is associated with better clinical outcomes, and allo-HST conferred no benefit in this patient group [34] similar to the core binding-factor leukemia patient group [35]. This evidence concerns the gene NPM1 and leukemia.